Lux Health Tech Acquisition Corp. (NASDAQ:LUXA) announced this afternoon that it has signed a non-binding letter of intent (LOI) to combine with a leading life sciences company.
The SPAC kept the details pertaining to the unnamed target to a minimum, but disclosed that the company has an experienced executive and scientific leadership team that has built an extensive technology platform with multiple programs in development. Lux Health Tech expects to offer the target its resources, experience and network of relationships to support growth and access to public markets.
Additionally, the target’s existing equity holders will be rolling over 100% of their equity into the combined public company. Little else is disclosed in the press release regarding the transaction, but Lux Health Tech expects to announce further information once the agreement is executed, which is expected to occur in the second half of 2022.
The SPAC announced the pricing of its $300 million IPO nearly two years ago in October 2020, and had initially set out to combine with a healthcare technology target with an experienced management team of serial entrepreneurs and acclaimed scientists. Lux Health is led by Chairman Peter Hébert, CEO and Director Josh DeFonzo and CFO and Treasurer Segolene Scarborough.
This LOI comes several weeks before its transaction deadline on October 20, 2022. But, since this deal is not at the “definitive agreement” stage, and is still at the non-binding LOI stage, SPACInsider will not consider this deal “announced”. As such, it will remain in the “Searching” category until a definitive agreement is signed.
Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...